Review
Sep 2026
CRISPR-Cas9‑based lipid nanocarriers for advanced therapy of urinary bladder cancer.
Bladder cancer (BCa) exhibits significant genetic and phenotypic variability. This variability suggests that various tumor subtypes could be influenced by several biomarkers and signaling pathways, which presents a problem for monotherapy strategies. Despite the initial effectiveness of traditional therapies, BCa's hig...
Swarupananda Mukherjee, D. Karati, Sinjini Sarkar et al.
· Nanomedicine · 0 citations